Table III.

Specific systemic induction of type 1 cytokines and down-regulation of IL-10 after SLC treatmenta

GroupIFN-γGM-CSFIL-10IL-12
Splenocytes
Mice without tumor, constitutive220 ± 300078 ± 1
Stimulated with 3LL85 ± 1937 ± 2016 ± 3
Diluent-treated, constitutive117 ± 41018 ± 160 ± 12
Stimulated with 3LL97 ± 1323 ± 9*1566 ± 9351 ± 1
SLC-treated, constitutive113 ± 21016 ± 1111 ± 1
Stimulated with 3LL2731 ± 99*71 ± 2*181 ± 14*206 ± 7*
Lymph node
Mice without tumor, constitutive248 ± 116 ± 1060 ± 1
Stimulated with 3LL87 ± 1234 ± 7048 ± 1
Diluent-treated, constitutive166 ± 1616 ± 1297 ± 1025 ± 1
Stimulated with 3LL96 ± 1752 ± 8816 ± 2584 ± 6
SLC-treated, constitutive256 ± 1019 ± 1025 ± 1
Stimulated with 3LL1242 ± 270*49 ± 6133 ± 17*108 ± 3*
  • a Splenic or lymph node-derived lymphocytes (5 × 106 cells/ml) were cultured with irradiated 3LL (105 cells/ml) tumors at a ratio of 50:1 in a total volume of 5 ml. After overnight culture, supernatants were harvested, and GM-CSF, IFN-γ, IL-12, and IL-10 were determined by ELISA. After stimulation with irradiated tumor cells, splenocytes and lymph node-derived cells from SLC-treated mice secreted significantly enhanced levels of IFN-γ, GM-CSF, and IL-12 but reduced levels of IL-10 compared with diluent-treated tumor-bearing mice. Results are expressed as picograms per milliliter. Experiments were repeated twice.

  • b , p < 0.01 compared with diluent-treated mice and SLC constitutive levels; n = 6 mice/group.